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Many proteins (intrinsically disordered proteins, IDPs) or regions of proteins (intrinsically disordered regions, IDRs) lack a well-defined 3D structure under physiological condi-
tions. Albeit unfolded and highly dynamic, these proteins are not denatured; rather, intrinsic structural disorder is their native, functional state. Structural disorder reaches high 
proportions in higher eukaryotes (35% of human proteins are predicted to possess IDRs consisting of at least 30 consecutive disordered residues). Disordered proteins play 
important roles in cell signaling and regulation, due to which IDPs/IDRs are also often involved in diseases.
Evidence for Structural Disorder of Proteins
There are multiple lines of evidence that structural disorder is the native state of IDPs. The primary techniques used for their characterization are NMR, SAXS, CD, and other 
biophysical techniques. Their results can be integrated using computational tools, which can yield structural ensembles, currently the best description of the unusual, highly 
dynamic structural state of IDPs. Also instrumental in studying structural disorder are bioinformatics tools, which can assess the ordered or disordered state based on an amino 
acid sequence. Data related to structural disorder are deposited in databases, such as PED (structural ensembles), DisProt (sequences and metadata), and MobiDB (predictions 
of disorder and other functional features). Experimental observations suggest that disorder encompasses a broad spectrum of distinct states, ranging from fully disordered to 
almost folded conformations.
Function by Induced Folding
The function of IDPs, intimately linked with their disorder, results either directly from their disordered state or from molecular recognition, when they undergo folding induced 
by interaction with their partner (another protein, DNA, RNA, or membrane). Induced folding (or disorder-to-order transitions), as observed for p53 binding to MDM2, E-cadherin 
binding to β-catenin, p27 binding to cyclin A/Cdk2, or the KID domain of CREB binding to the KIX domain of CBP, for example, may entail different advantages such as fast bind-
ing kinetics (also termed fly casting), regulation by post-translational modifications (PTMs), structural adaptability to multiple partners (functional pleiotropy, or moonlighting), 
and “uncoupling” specificity from binding strength. Disorder-to-order transition upon binding may proceed by two extreme mechanisms, conformational selection or induced fit 
(binding-induced folding), as illustrated by the example of the CREB KID binding to CBP KIX.
Peptide Motifs—Recognition Elements of IDPs
The interactions of IDPs/IDRs are most often mediated by short interaction modules, referred to as peptide motifs (also called short linear motifs, SLiMs, or eukaryotic linear 
motifs, ELMs). Peptide motifs are typically <10 residues in length, they prefer to be located within protein IDRs, and based on the presence of a few highly conserved, specificity-
determining residues, they are recognized and/or modified by structured domains of their interacting partners. There are six different functional outcomes of motif recognition, 
including targeting, regulated degradation, or post-translational modifications. Due to their short length, peptide motifs usually engage in weak and transient interactions.
Molecular Mechanisms of IDPs
Intrinsically disordered proteins cannot have functions typical for folded proteins, such as enzymatic activity, and their very existence defies the classical structure-function 
paradigm. Sometimes their function stems directly from the disordered state, without partner binding, termed the entropic chain mechanism (e.g., in the nuclear pore complex). 
An entropic chain can generate force, allow functional inter-domain motions, reach out for remote binding partners, or simply keep proteins apart using a spacer mechanism. 
Very often, however, IDPs function by molecular recognition, when their motifs (SLiMs) or longer regions (disordered domains) undergo a folding transition induced by the part-
ner. When binding is transient, it can lead to modification (display site, e.g., pro-insulin) or chaperone actions (e.g., Hsp90). In case of permanent binding, disorder results in 
the assembly of multi-protein complexes (e.g., scaffold proteins like Ste5), modification of the activity of the partner (e.g., p27 inhibiting Cdk2/cyclin A), or scavenging of small 
molecules (e.g., casein binding to calcium phosphate).
Structural Disorder in Signaling, Regulation, and Disease
The functional advantages of structural disorder, such as fast binding kinetics, facile regulation by PTMs, high functional density, and specificity without strong binding 
(reversibility), are all potentially beneficial in signaling and regulatory tasks, when fast responses to changes in the external or internal environment are critical for cellular fitness 
and survival. Accordingly, structural disorder abounds in proteins with signaling and regulatory functions (as illustrated by the G1➝S restriction point pathway, proteins with at 
least one long disordered region marked by asterisk). For example, disorder can reach very high levels in transcription factors, chromatin-organizing proteins, signaling adaptors 
and scaffolds, cytoskeletal proteins, and cell-cycle regulatory proteins. For apparently the very same reasons, higher eukaryotes that rely on complex regulatory decisions to 
harmonize the operation of their multiple cell types possess high levels of disorder (about 30% of their residues fall into disordered regions). Due to its prominent roles in signal-
ing, structural disorder also reaches high levels in disease-associated proteins, and some of the most-studied proteins, such as α-synuclein, tau protein, c-Myc, and p53, are 
noted for their high disorder content, due to which IDPs are also attractive targets in drug development efforts.
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